Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua J Short

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|August 13, 2009
Oncolytic adenoviruses targeted to cancer stem cellsJoshua J Short, David T Curiel
Virus Research|August 22, 2006
Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptorsJoshua J Short, Chenthamarakshan Vasu, Mark J Holterman, et al.
Virology|April 28, 2004
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptorsJoshua J Short, Alexander V Pereboev, Yosuke Kawakami, et al.
Molecular Cancer Therapeutics|August 26, 2010
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacyJoshua J Short, Angel A Rivera, Hongju Wu, et al.
Virology|May 22, 2003
A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropismKoichi Takayama, Paul N Reynolds, Joshua J Short, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|August 13, 2009
Oncolytic adenoviruses targeted to cancer stem cellsJoshua J Short, David T Curiel
Virus Research|August 22, 2006
Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptorsJoshua J Short, Chenthamarakshan Vasu, Mark J Holterman, et al.
Virology|April 28, 2004
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptorsJoshua J Short, Alexander V Pereboev, Yosuke Kawakami, et al.
Molecular Cancer Therapeutics|August 26, 2010
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacyJoshua J Short, Angel A Rivera, Hongju Wu, et al.
Virology|May 22, 2003
A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropismKoichi Takayama, Paul N Reynolds, Joshua J Short, et al.
Pageof 1